Innovative Pharmaceutical Biotech Limited (HKG:0399)
Hong Kong
· Delayed Price · Currency is HKD 0.2050
-0.0070 (-3.30%)
Jun 13, 2025, 4:08 PM HKT
HKG:0399 Income Statement
Financials in millions HKD. Fiscal year is April - March.
Millions HKD. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 | 2015 - 2019 |
| Revenue | 5.9 | 6.59 | 8.08 | 11.15 | 15.19 | 14.58 | Upgrade
|
| Revenue Growth (YoY) | -23.08% | -18.35% | -27.55% | -26.63% | 4.18% | -21.57% | Upgrade
|
| Cost of Revenue | 5.13 | 5.75 | 7.22 | 10.09 | 13.78 | 12.96 | Upgrade
|
| Gross Profit | 0.77 | 0.84 | 0.86 | 1.05 | 1.41 | 1.62 | Upgrade
|
| Selling, General & Admin | 13.31 | 12.92 | 17.03 | 17.24 | 16.91 | 22.64 | Upgrade
|
| Research & Development | 1.83 | 1.42 | 4.76 | 8.25 | 6.09 | 11.34 | Upgrade
|
| Operating Expenses | 15.14 | 14.34 | 21.79 | 25.49 | 23 | 33.98 | Upgrade
|
| Operating Income | -14.37 | -13.5 | -20.93 | -24.44 | -21.6 | -32.36 | Upgrade
|
| Interest Expense | -202.86 | -218.1 | -233.97 | -189.95 | -191.03 | -147.04 | Upgrade
|
| Interest & Investment Income | - | - | - | 0 | 0.03 | 0.02 | Upgrade
|
| Earnings From Equity Investments | - | - | - | - | - | 6.31 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.07 | 0.07 | 0.18 | 0.16 | -0.06 | -0.22 | Upgrade
|
| EBT Excluding Unusual Items | -217.17 | -231.53 | -254.72 | -214.22 | -212.66 | -173.29 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | - | - | -27.4 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | - | 0.29 | - | Upgrade
|
| Other Unusual Items | 224.26 | 330.24 | 0.05 | 250.65 | 0.21 | -21.78 | Upgrade
|
| Pretax Income | 7.1 | 98.71 | -254.67 | 36.43 | -212.16 | -222.46 | Upgrade
|
| Earnings From Continuing Operations | 7.1 | 98.71 | -254.67 | 36.43 | -212.16 | -222.46 | Upgrade
|
| Net Income to Company | 7.1 | 98.71 | -254.67 | 36.43 | -212.16 | -222.46 | Upgrade
|
| Minority Interest in Earnings | 4.36 | 4.7 | 8.97 | 9.37 | 7.22 | 11.35 | Upgrade
|
| Net Income | 11.46 | 103.4 | -245.7 | 45.8 | -204.94 | -211.12 | Upgrade
|
| Net Income to Common | 11.46 | 103.4 | -245.7 | 45.8 | -204.94 | -211.12 | Upgrade
|
| Shares Outstanding (Basic) | 1,662 | 1,527 | 1,464 | 1,464 | 1,464 | 1,464 | Upgrade
|
| Shares Outstanding (Diluted) | 3,341 | 2,499 | 1,464 | 1,750 | 1,464 | 1,464 | Upgrade
|
| Shares Change (YoY) | 107.89% | 70.64% | -16.34% | 19.53% | - | - | Upgrade
|
| EPS (Basic) | 0.01 | 0.07 | -0.17 | 0.03 | -0.14 | -0.14 | Upgrade
|
| EPS (Diluted) | 0.00 | -0.01 | -0.17 | -0.04 | -0.14 | -0.14 | Upgrade
|
| Free Cash Flow | -6.53 | -8.28 | -17.64 | -12.34 | -25.01 | -36.22 | Upgrade
|
| Free Cash Flow Per Share | -0.00 | -0.00 | -0.01 | -0.01 | -0.02 | -0.03 | Upgrade
|
| Gross Margin | 13.01% | 12.74% | 10.63% | 9.46% | 9.25% | 11.11% | Upgrade
|
| Operating Margin | -243.82% | -204.76% | -259.21% | -219.25% | -142.19% | -221.94% | Upgrade
|
| Profit Margin | 194.33% | 1568.38% | -3042.70% | 410.97% | -1349.26% | -1447.99% | Upgrade
|
| Free Cash Flow Margin | -110.79% | -125.57% | -218.45% | -110.68% | -164.63% | -248.45% | Upgrade
|
| EBITDA | - | -11.62 | -19.05 | -22.31 | -21.56 | -32.3 | Upgrade
|
| EBITDA Margin | - | -176.23% | -235.91% | -200.13% | -141.96% | -221.53% | Upgrade
|
| D&A For EBITDA | - | 1.88 | 1.88 | 2.13 | 0.04 | 0.06 | Upgrade
|
| EBIT | -14.37 | -13.5 | -20.93 | -24.44 | -21.6 | -32.36 | Upgrade
|
| EBIT Margin | -243.82% | -204.76% | -259.21% | -219.25% | -142.19% | -221.94% | Upgrade
|
Updated Dec 27, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.